WOBURN, Mass.--(BUSINESS WIRE)--Nuvera Biosciences, a molecular diagnostics company, reports significant advances in breast cancer genomic assays on endocrine therapy and chemotherapy outcomes. The research performed in collaboration with The University of Texas M.D. Anderson Cancer Center will be presented at the ASCO Annual Meeting in Chicago as five poster presentations on June 2, 2008.
